Summary: An outbreak of anticonvulsant intoxication occurred in epileptic patients in Australia during 1968-9. All affected patients studied in Brisbane were taking one brand-of phenytoin. In 87% of them the blood phenytoin levels were above the therapeutic range. Reduction of phenytoin dosage relieved the intoxication in all patients. The excipient in the responsible phenytoin capsules had been changed several months before the outbreak, and this change was probably related causally to the altered blood phenytoin concentrations.
Introduction
While anticonvulsant overdosage is accepted as an occasional hazard in the drug treatment of epilepsy, it certainly is not usual to encounter within a period of several months many epileptic patients who have previously taken anticonvulsant therapy without ill effect and who have then almost simultaneously developed manifestations of drug intoxication. Yet such an event occurred in various cities in Australia during 1968 (Balla, 1968; Eadie et al., 1968; Rail, 1968) . The present paper recounts an experience of this "epidemic" of anticonvulsant intoxication seen in the City of Brisbane, which draws on the population of south-eastern Queensland (about one million people), and describes preliminary attempts to determine the factors responsible for the outbreak. I drug intoxication it was found that in two-thirds of the patients it had been necessary to reduce the phenytoin dosage prescribed by 20-40 0/, and in another one-quarter of the patients by more than 400,,.
Blood Phenytoin Concentrations
That the epidemic of anticonvulsant intoxication was due to phenytoin overdosage was confirmed by measurements of blood phenytoin concentrations performed in 39 of the 51 patients (Table III) . The phenytoin assay method developed by Wallace (1966) was used for the estimations. Blood for phenytoin estimation was sometimes taken after anticonvulsant therapy had been stopped, so that the concentrations may not always have been the maximal ones present in indi- ,ug./ml.) (Table III) . In three patients we had measured blood phenytoin concentrations before intoxication occurred and again during intoxication: levels of 6.5, 7-5, and 12.6 gg./ml, rose to 24.2, 33-0, and 20.4 /ig./ml., respectively.
Cause of the Outbreak Phenytoin Preparation Responsible
Once it was realized that the epidemic was one of phenytoin intoxication and that all affected patients were taking the one brand of 100-mg. phenytoin sodium capsules, these particular capsules were suspected of containing more than 100 mg. of phenytoin sodium. However, using the Wallace (1966) method, assay of the phenytoin content of several capsules from the batches being taken by different patients at the times when they developed drug intoxication showed amounts of phenytoin ranging between 92 and 98 mg. per capsule. Clearly the capsules did not contain excess drug. Therefore the less likely possibility that all previous phenytoin sodium capsules produced by the particular manufacturer had contained too little drug was explored. When two of this manufacturer's 100-mg. phenytoin sodium capsules which had been made four years previously and which were being used in a drug trial were analysed they contained 99 and 100 mg. of drug, sulphate, and in mid-1967 we had begun to see an unusual number of cases which were clinically diagnosed as probable phenytoin intoxication, but the outbreak ceased before we were in a position to investigate it.
Effect of Changed Excipient in Capsules
The above evidence suggests a possible causal relation between the change in excipient and the outbreak of phenytoin intoxication. Direct evidence for such a relation was obtained in one patient (see Chart) in whom serial blood phenytoin concentrations were estimated while his treatment was changed from phenytoin with lactose excipient to phenytoin with calcium sulphate excipient and then back to phenytoin with lactose excipient, there being no significant change in the daily amount of phenytoin ingested at any stage. This patient's blood phenytoin concentration fell rapidly to a quarter of its former value when the phenytoin with calcium sulphate excipient was used instead of phenytoin with lactose excipient. The blood phenytoin concentration rose again when phenytoin (lactose excipient) was reintroduced. The 24-hour faecal phenytoin excretion was measured at the time of the change over of the two preparations. There was no increase in faecal phenytoin loss at the time of the fall in blood phenytoin concentration, which suggested that the decrease in blood phenytoin was not due to increased faecal phenytoin loss. Subsequently serial blood phenytoin concentrations were measured in three further patients who were changed from phenytoin with calcium sulphate excipient to phenytoin with lactose excipient without change in phenytoin dose. In all instances the preparation with lactose excipient produced substantially higher blood phenytoin concentrations (see Table  IV ). Two months later he was readmitted with femoral artery thrombosis. Right midthigh amputation was performed, and on examination the femoral artery and its branches were occluded.
There was medial hyperplasia and intimal proliferation, but no evidence of arteritis or any atherosclerosis. On coagulation study platelets were normal in number, morphology, adhesiveness, and aggregation; fibrinogen levels, prothrombin time, and thrombotest were also normal. The thromboplastin generation test (Biggs and Douglas, 1953) , however, showed an accelerated pattern on two occasions (see Table and Fig. 1 ). The patient's plasma, and particularly the serum, produced an intermediate degree of acceleration when mixed with normal serum or plasma, respectively. At this time he had two weakly positive L.E. cell tests out of four, but subsequent tests had been negative. Complete clinical remission has since occurred with immunosuppressive therapy.
Case 2
A 35-year-old Chinese was admitted to hospital for swelling of the legs. He had had a similar illness when he was 10 years old. Features of the nephrotic syndrome were found on clinical examination and laboratory investigations. The serum cholesterol was very high at 950 mg./100 ml. Total serum proteins were 4-2 g./100 ml. and albumin 2-0 g./100 ml. The daily urinary protein varied from 5 to 10 g. The bleeding, clotting, and prothrombin times were normal; L.E. cell tests were negative on three occasions. No specific changes by light microscopy were seen in the renal biopsy specimen, and the nephrotic syndrome of "minimal change" type (Habib et al., 1961) was diagnosed. At discharge the patient was on 45mg. of prednisolone daily. After being sympton-free for 10 months he was readmitted for exacerbation of the nephrotic syndrome. During this admission he developed substernal chest pain due to anterior myocardial infarction.
Serum cholesterol ranged from 1,300 to 1,900mg./100ml. Coagulation studies showed no platelet abnormality; plasma fibrinogen levels, prothrombin time, and thrombotest were normal. There was, however, definite acceleration of thromboplastin generation on three occasions over a three-month period (see Table and 
